Merus to Present at Upcoming Investor Conferences

MRUS 11.06.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-12
Name of Upcoming Event:Guggenheim Securities Healthcare Innovation Conference
Date of Upcoming Event:2024-11-18
Name of Upcoming Event:Stifel 2024 Healthcare Conference
Full Press ReleaseSEC FilingsOur MRUS Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - Merus et Biohaven annoncent une collaboration pour co-développer trois nouveaux programmes de CAM bispécifiques
  • 01.13.2025 - Merus und Biohaven geben Zusammenarbeit bei der gemeinsamen Entwicklung von drei neuartigen bispezifischen ADC-Programmen bekannt
  • 01.13.2025 - Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

Recent Filings

  • 12.16.2024 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
PDF Version

UTRECHT, The NetherlandsandCAMBRIDGE, Mass.,Nov. 06, 2024(GLOBE NEWSWIRE) --Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics®and Triclonics®), today announced thatBill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences:

  • Guggenheim Securities Healthcare Innovation Conference(fireside chat):Tuesday, November 12at9:30 a.m. ET
  • Stifel 2024 Healthcare Conference (fireside chat):Monday, November 18at3:00 p.m. ET

The webcasts of the presentations will be contemporaneously available on theInvestors pageof the Company's website. The archived presentations will also be available there for a limited time after the event.

About MerusMerusis a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to asMulticlonics®. Multiclonics®are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visitMerus’ website,XandLinkedIn.

Multiclonics®, Biclonics®and Triclonics®are registered trademarks ofMerus N.V.

Investor and Media Inquiries:Sherri SpearMerus N.V.SVP Investor Relations and Strategic Communications617-821-3246s.spear@merus.nlKathleen FarrenMerus N.V.Assoc. Director IR/Corp Comms617-230-4165k.farren@merus.nl

Primary Logo

Source: Merus N.V.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com